Although there are remaining specific biomarkers and clinical characteristics to assess the risk of BCR, including PSA level of pretherapy, tumor stage, and Gleason score (GS), these factors seem incapable of comprehensively evaluating the risk of BCR for patients (Kretschmer and Tilki, 2017; Mottet et al., 2021). Here, BCR is linked to neoplasm.